A phase II study of carboplatin, pemetrexed, and bevacizumab followed by erlotinib and bevacizumab maintenance for non-squamous non-small cell lung cancer with wild-type EGFR (HOT1101)

[1] Jemal A(2010)Cancer statistics, 2010 CA Cancer J Clin 60 277-300

[2] Siegel R(2001)Global cancer statistics in the year 2000 Lancet Oncol 2 533-543

[3] Xu J(2015)Impact of specific epidermal growth factor receptor (EGFR) mutations and clinical characteristics on outcomes after treatment with EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR-mutant lung cancer: a meta-analysis J Clin Oncol 33 1958-1965

[4] Parkin DM(2013)Crizotinib versus chemotherapy in advanced ALK-positive lung cancer N Engl J Med 368 2385-2394

[5] Lee CK(2017)Oncogene addiction in non-small cell lung cancer: focus on ROS1 inhibition Cancer Treat Rev 55 83-95

[6] Wu YL(2016)Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer N Engl J Med 375 1823-1833

[7] Ding PN(2010)Who are less likely to receive subsequent chemotherapy beyond first-line therapy for advanced non-small cell lung cancer? Implications for selection of patients for maintenance therapy J Thorac Oncol 5 540-545

[8] Shaw AT(2011)Predictors and impact of second-line chemotherapy for advanced non-small cell lung cancer in the United States: real-world considerations for maintenance therapy J Thorac Oncol 6 365-371

[9] Kim DW(2009)Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer J Clin Oncol 27 591-598

[10] Nakagawa K(2012)Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer J Clin Oncol 30 3516-3524

[1] Jemal A(2010)Cancer statistics, 2010 CA Cancer J Clin 60 277-300

[2] Siegel R(2001)Global cancer statistics in the year 2000 Lancet Oncol 2 533-543

[3] Xu J(2015)Impact of specific epidermal growth factor receptor (EGFR) mutations and clinical characteristics on outcomes after treatment with EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR-mutant lung cancer: a meta-analysis J Clin Oncol 33 1958-1965

[4] Parkin DM(2013)Crizotinib versus chemotherapy in advanced ALK-positive lung cancer N Engl J Med 368 2385-2394

[5] Lee CK(2017)Oncogene addiction in non-small cell lung cancer: focus on ROS1 inhibition Cancer Treat Rev 55 83-95

[6] Wu YL(2016)Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer N Engl J Med 375 1823-1833

[7] Ding PN(2010)Who are less likely to receive subsequent chemotherapy beyond first-line therapy for advanced non-small cell lung cancer? Implications for selection of patients for maintenance therapy J Thorac Oncol 5 540-545

[8] Shaw AT(2011)Predictors and impact of second-line chemotherapy for advanced non-small cell lung cancer in the United States: real-world considerations for maintenance therapy J Thorac Oncol 6 365-371

[9] Kim DW(2009)Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer J Clin Oncol 27 591-598

[10] Nakagawa K(2012)Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer J Clin Oncol 30 3516-3524